Acadia Pharmaceuticals Balance Sheet
ACAD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 15 fiscal years. All figures from audited SEC 10-K filings.
Acadia Pharmaceuticals had $1.6B in total assets and $1.2B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M | $326.0M | $189.7M | $134.8M | $69.4M | $163.6M | $102.1M | $57.9M | $11.7M | $57.9M | $6.9M |
| Accounts Receivable | $121.5M | $98.7M | $98.3M | $62.2M | $64.4M | $48.2M | $35.8M | $26.1M | $17.3M | $5.9M | - | - | - | - | - |
| Inventory | $111.4M | $91.7M | $40.4M | $11.6M | $14.1M | $9.7M | $6.3M | $4.1M | $5.2M | $4.2M | - | - | - | - | - |
| Current Assets | $1.1B | $938.3M | $616.1M | $507.9M | $617.8M | $717.6M | $760.3M | $526.1M | $373.5M | $547.9M | $219.0M | $324.6M | $188.4M | $108.5M | $31.9M |
| PP&E (Net) | $7.5M | $4.2M | $4.6M | $6.0M | $8.0M | $9.2M | $3.2M | $3.3M | $2.7M | $3.1M | $2.2M | $553.0K | $579.0K | $42.0K | $151.0K |
| Total Assets | $1.6B | $1.2B | $749.0M | $587.8M | $700.1M | $782.6M | $783.2M | $540.2M | $384.5M | $561.2M | $221.9M | $325.5M | $189.1M | $108.6M | $32.1M |
| Current Liabilities | $277.1M | $394.9M | $254.3M | $125.6M | $96.1M | $106.0M | $74.8M | $59.6M | $49.0M | $42.6M | $21.9M | $15.8M | $7.0M | $5.9M | $6.2M |
| Shareholders' Equity | $1.2B | $732.8M | $431.8M | $400.4M | $540.9M | $627.0M | $699.1M | $479.1M | $335.3M | $518.4M | $199.8M | $85.0M | $182.1M | $85.0M | $23.4M |